CLINICAL TRIALS PROFILE FOR LEQVIO

All Clinical Trials for LEQVIO

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT05004675 ↗	Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients	Not yet recruiting	Medpace, Inc.	Phase 3	2021-10-15	Comparison of LDL-C reductions of lerodalcibep (LIB003) 300 mg to inclisiran (Leqvio®) 284 in patients at very-high risk or high-risk for CVD on stable diet and oral LDL-C-lowering drug therapy
NCT05004675 ↗	Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients	Not yet recruiting	LIB Therapeutics LLC	Phase 3	2021-10-15	Comparison of LDL-C reductions of lerodalcibep (LIB003) 300 mg to inclisiran (Leqvio®) 284 in patients at very-high risk or high-risk for CVD on stable diet and oral LDL-C-lowering drug therapy
NCT05834673 ↗	VICTORION-ASCERTAIN: Implementation Study (v-ASCERTAIN)	Recruiting	Novartis Pharmaceuticals	Phase 4	2023-11-17	The goal of this study is to understand and compare an alternative model of care in comparison to the usual model of care in include male and female participants ≥18 years of age with a history of ASCVD (hear and blood vessels diseases) or high-risk participants who have elevated bad cholesterol (LDL-C ≥1.8 mmol/L). The alternative model of care includes telephone support calls from a study nurse (after visits 1,2 and 4) and text messages to your mobile phone with healthy heart information. The main question it aims to answer is to understand and compare an alternative model of care in comparison to the usual model of care by evaluating the study participants bad cholesterol values after 180 and 365 days of the study. Each participant will take their medications as per usual care but may have the addition of Inclisiran, 284 mg 1.5 ml liquid in a single-use prefilled syringe for under skin administration. In accordance with the current medical practice guidelines for treating heart related conditions, Inclisiran and its product information will be made available for use in both care models. All the participants who decide to take part in this study will be requested to do the following: - Answer any questions from the study doctor or the study staff as accurately as possible when asked about changes in health status, medications, heart health, visits to other doctors or hospital admissions, planned surgery, even if they think none of these are related to the study. - Study doctor will be able to inform them of which medications you can and cannot take as part of this study. - To use mobile phone to receive text messages and/or questionnaires as proposed in the new model of care. - Advise the study doctor if they plan to move away from the geographical area where the study is being conducted during the study period. - Take the medications for cholesterol lowering treatment (such as a statin and/or ezetimibe) that are prescribed by the study doctor. - Tell the study doctor or study staff as soon as possible about suspected participant / participant partner pregnancy. - Tell the study doctor or study staff if they change their mind about taking part in the study. - Attend all the visits (screening visit, visits 1, 2, 3, 4 and visit 5). - Provide all the information that will enable the study team to contact them, i.e., inform the study staff if contact details change, provide contact details of a family member, etc.
NCT05834673 ↗	VICTORION-ASCERTAIN: Implementation Study (v-ASCERTAIN)	Recruiting	Monash University	Phase 4	2023-11-17	The goal of this study is to understand and compare an alternative model of care in comparison to the usual model of care in include male and female participants ≥18 years of age with a history of ASCVD (hear and blood vessels diseases) or high-risk participants who have elevated bad cholesterol (LDL-C ≥1.8 mmol/L). The alternative model of care includes telephone support calls from a study nurse (after visits 1,2 and 4) and text messages to your mobile phone with healthy heart information. The main question it aims to answer is to understand and compare an alternative model of care in comparison to the usual model of care by evaluating the study participants bad cholesterol values after 180 and 365 days of the study. Each participant will take their medications as per usual care but may have the addition of Inclisiran, 284 mg 1.5 ml liquid in a single-use prefilled syringe for under skin administration. In accordance with the current medical practice guidelines for treating heart related conditions, Inclisiran and its product information will be made available for use in both care models. All the participants who decide to take part in this study will be requested to do the following: - Answer any questions from the study doctor or the study staff as accurately as possible when asked about changes in health status, medications, heart health, visits to other doctors or hospital admissions, planned surgery, even if they think none of these are related to the study. - Study doctor will be able to inform them of which medications you can and cannot take as part of this study. - To use mobile phone to receive text messages and/or questionnaires as proposed in the new model of care. - Advise the study doctor if they plan to move away from the geographical area where the study is being conducted during the study period. - Take the medications for cholesterol lowering treatment (such as a statin and/or ezetimibe) that are prescribed by the study doctor. - Tell the study doctor or study staff as soon as possible about suspected participant / participant partner pregnancy. - Tell the study doctor or study staff if they change their mind about taking part in the study. - Attend all the visits (screening visit, visits 1, 2, 3, 4 and visit 5). - Provide all the information that will enable the study team to contact them, i.e., inform the study staff if contact details change, provide contact details of a family member, etc.

Clinical Trial Conditions for LEQVIO

Condition Name

Condition Name for LEQVIO
Intervention	Trials
Atherosclerosis	1
Atherosclerotic Cardiovascular Disease (ASCVD)	1
Atherosclerotic Ischemic Disease	1
Cerebrovascular Disease	1

Condition MeSH

Condition MeSH for LEQVIO
Intervention	Trials
Coronary Artery Disease	2
Atherosclerosis	2
Hypercholesterolemia	1
Heart Diseases	1

Clinical Trial Locations for LEQVIO

Trials by Country

Trials by Country for LEQVIO
Location	Trials
Australia	1
United States	1

Trials by US State

Trials by US State for LEQVIO
Location	Trials
Kentucky	1

Clinical Trial Progress for LEQVIO

Clinical Trial Phase

Clinical Trial Phase for LEQVIO
Clinical Trial Phase	Trials
PHASE4	1
Phase 4	1
Phase 3	1

Clinical Trial Status

Clinical Trial Status for LEQVIO
Clinical Trial Phase	Trials
Not yet recruiting	1
Recruiting	1
WITHDRAWN	1

Clinical Trial Sponsors for LEQVIO

Sponsor Name

Sponsor Name for LEQVIO
Sponsor	Trials
Medpace, Inc.	1
LIB Therapeutics LLC	1
Novartis Pharmaceuticals	1

Sponsor Type

Sponsor Type for LEQVIO
Sponsor	Trials
Industry	3
Other	2

Leqvio (inclisiran): Clinical Trials Update, Market Analysis, and Future Projections

Last updated: January 24, 2026

Executive Summary

Leqvio (inclisiran) is a lipid-lowering agent developed by Novartis, approved in the European Union in December 2020 and in the U.S. in December 2021 for the treatment of heterozygous familial hypercholesterolemia (HeFH) and clinical atherosclerotic cardiovascular disease (ASCVD). This article provides a comprehensive review of ongoing clinical trials, current market landscape, competitive positioning, and future market projections for inclisiran. It synthesizes recent data, regulatory updates, and market trends to assist stakeholders in strategic decision-making.

---

What is the Current Status of Clinical Trials for Leqvio?

Overview of Clinical Trials

Inclisiran has undergone extensive Phase 3 trials demonstrating its efficacy in decreasing low-density lipoprotein cholesterol (LDL-C). Key trials include ORION series:

Trial Name	Phase	Completion Date	Population	Primary Endpoint	Key Findings
ORION-9	3	June 2020	HeFH	LDL-C reduction	Statistically significant LDL-C reduction (~50%) at 17 months
ORION-10	3	December 2020	ASCVD	LDL-C reduction	52% LDL-C reduction vs placebo (p<0.001)
ORION-11	3	December 2020	ASCVD	LDL-C reduction	52.3% LDL-C reduction (p<0.001)
ORION-4	3/4	Ongoing (Estimated 2024)	ASCVD	CV events	Cardiovascular outcomes trial; initial results expected in 2024

Ongoing and Upcoming Trials

Trial Name	Purpose	Estimated Completion	Notes
ORION-5 (NCT05147315)	Pediatric hypercholesterolemia	2023-2025	Assess safety and efficacy in children
ORION-8	Secondary prevention in broader populations	2024	Expanding indications
ORION-12	Long-term safety and durability of LDL-C lowering	2023-2026	Post-marketing surveillance

Regulatory Updates

• United States: FDA approval granted in December 2021; priority review with a label covering HeFH and ASCVD.
• European Union: EMA approval in December 2020; included in guidelines for lipid management.
• Other Markets: Japan, Canada, and Australia approvals ongoing or under review.

---

Market Analysis: Current Landscape and Competitive Positioning

Market Size and Growth Drivers

Metric	2022 Estimate	Projected 2027	CAGR 2023–2027	Source
Global LDL-C lowering drugs market	$27 billion	$37 billion	6.5%	MarketsandMarkets
Inclisiran Market Share (2022)	<5%	15% (2027)	N/A	Novartis, Industry analysts

Market Drivers

• Rise in Dyslipidemia & Cardiovascular Disease: Global increase due to aging populations and obesity.
• Unmet Need for Durable LDL-C Lowering: Inclisiran offers ~3-4 month dosing, improving adherence compared to statins and PCSK9 inhibitors.
• Guideline Endorsements: ESC/EAS (European Society of Cardiology/European Atherosclerosis Society) recommends inclisiran for high-risk patients.

Competitive Landscape

Competitors	Mechanism of Action	Key Products	Market Share	Strengths
PCSK9 inhibitors (evolocumab, alirocumab)	Monoclonal antibodies	Repatha, Praluent	60%	Proven efficacy, well-established
Statins	HMG-CoA reductase inhibitors	Lipitor, Crestor	30%	Cost-effective, broad use
Bempedoic acid	ATP citrate lyase inhibitor	Nexletol	5%	Oral administration, incremental benefits
Inclisiran	siRNA-based LDL receptor silencing	Leqvio (Novartis)	5% (2022)	Twice-yearly dosing, favorable safety profile

Market Challenges

• Pricing and Reimbursement: Inclisiran's premium pricing relative to generic statins.
• Physician Familiarity and Adoption: Slow initial uptake due to established therapy patterns.
• Long-term Safety Data: Awaiting long-term outcome data to solidify positioning.

---

Market Projection & Revenue Forecasts

2023–2027 Revenue Projections for Inclisiran

Year	Estimated Revenue (USD millions)	Assumptions
2023	$300	Initial adoption in high-risk populations; emerging markets entering the fray
2024	$600	Expanded indications; increased clinician familiarity
2025	$1,000	Greater payor acceptance; inclusion in clinical guidelines
2026	$1,500	Dominance in niche hypercholesterolemia segment
2027	$2,000	Broader cardiovascular prevention use

Factors Influencing Revenue Growth

• Regulatory approvals for additional indications (e.g., primary prevention, pediatrics).
• Payer coverage and reimbursement policies.
• Clinical outcomes data demonstrating superior or comparable efficacy.
• Pricing strategies and market penetration in emerging regions.

---

Deep Dive: Comparative Effectiveness and Positioning

Aspect	Inclisiran	PCSK9 inhibitors	Statins
Dosing Frequency	Biannual (every 3-4 months)	Biweekly or monthly	Daily
Administration Route	Subcutaneous injection	Subcutaneous injection	Oral
LDL-C Reduction	~50%	50-60%	20-55% (depending on statin)
Safety Profile	Well tolerated; mild injection site reactions	Well tolerated; rare neurocognitive events	Well known, some risk of muscle symptoms
Adherence Potential	High (due to infrequent dosing)	Moderate	Variable

Regulatory and Policy Outlook

Region	Status	Anticipated Changes
US (FDA)	Approved (Dec 2021)	Long-term CV outcomes study ongoing
EU (EMA)	Approved (Dec 2020)	Inclusion in lipid management guidelines
Japan	Under review	Expected approval in 2023
Emerging Markets	Pending submissions	Growth opportunities

---

Key Takeaways

1. Clinical Evidence Validates Efficacy: Inclisiran consistently reduces LDL-C by approximately 50% across diverse patient populations, with ongoing trials exploring cardiovascular outcomes.
2. Market Adoption Accelerating: Driven by prolonged dosing interval, safety profile, and guideline endorsements, inclisiran's market share is expected to grow significantly in the next five years.
3. Competitive Edge is Dosing Convenience: Infrequent, biannual injections position inclisiran favorably against monoclonal antibody PCSK9 inhibitors.
4. Pricing and Reimbursement are Critical Barriers: Market growth hinges on favorable payer policies and demonstration of cost-effectiveness in broader healthcare settings.
5. Long-Term Outcomes Data Will Clarify Positioning: Results from outcomes trials like ORION-4 are pivotal to solidify inclisiran's role in primary and secondary prevention protocols.

---

FAQs

Q1: How does inclisiran's mechanism of action differ from existing lipid-lowering therapies?
Inclisiran is a small interfering RNA (siRNA) that targets PCSK9 mRNA in the liver, reducing PCSK9 protein synthesis, thereby increasing LDL receptor recycling and enhancing LDL clearance. Unlike monoclonal antibodies (e.g., evolocumab), which neutralize circulating PCSK9, inclisiran suppresses its production at the gene expression level.

Q2: What are the main safety concerns associated with inclisiran?
Clinical trials report a favorable safety profile with mild injection site reactions being the most common adverse event. Long-term safety data are still being accumulated; however, no significant neurocognitive or hepatorenal toxicity signals have emerged.

Q3: What patient populations are most likely to benefit from inclisiran?
Patients with heterozygous familial hypercholesterolemia, those with established ASCVD requiring sustained LDL-C lowering, and individuals intolerant to statins stand to benefit most. Future indications may include primary prevention in high-risk populations.

Q4: How does inclisiran impact healthcare resource utilization?
The biannual dosing may improve adherence, potentially reducing cardiovascular events and associated hospitalizations. However, the upfront cost and administration logistics could offset short-term savings unless offset by improved outcomes.

Q5: What are the key regulatory challenges facing inclisiran in emerging markets?
Regulatory pathways vary; some markets lack established pathways for siRNA-based drugs. Demonstrating cost-effectiveness, securing reimbursement, and establishing manufacturing quality are critical hurdles.

---

References

1. ORION Clinical Trial Series. Novartis, 2019–2022.
2. European Medicines Agency (EMA). Leqvio Summary of Product Characteristics, 2020.
3. US Food and Drug Administration (FDA). Leqvio Approval Letter, 2021.
4. MarketsandMarkets. Lipid Management Market Report, 2022.
5. European Society of Cardiology (ESC). Guidelines on Cardiovascular Prevention, 2021.

---

This analysis is intended for professionals and stakeholders to inform strategic decisions related to inclisiran's clinical development, commercialization, and positioning within the lipid-lowering therapeutic landscape.